Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001104659-25-059524 0001813314 XXXXXXXX LIVE 7 Common Stock, par value $0.0001 per share 05/15/2026 0001763950 51654W101 Lantern Pharma Inc. 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 Bios Equity Partners, LP 817-984-9197 1751 River Run Suite 400 Fort Worth TX 76107 0001813844 BIOS ADVISORS GP, LLC b AF N TX 0 571305 0 571305 571305 N 4.48 PN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001789490 AARON G.L. FLETCHER b AF OO N X1 0 571305 0 571305 571305 N 4.48 IN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813270 CAVU MANAGEMENT, LP b AF N TX 0 571305 0 571305 571305 N 4.48 PN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813310 CAVU ADVISORS, LLC b AF N TX 0 571305 0 571305 571305 N 4.48 PN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813316 LESLIE W. KREIS b AF OO N X1 0 571305 0 571305 571305 N 4.48 IN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813314 BIOS EQUITY PARTNERS, LP b AF N TX 0 266621 0 266621 266621 N 2.09 PN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP (Bios Equity I) is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813313 BIOS EQUITY PARTNERS II, LP b AF N TX 0 304684 0 304684 304684 N 2.39 PN Shared voting and dispositive power consists of (i) 64,794 Shares directly held by Bios Fund II, (ii) 211,566 Shares directly held by Bios Fund II QP and (iii) 28,324 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP (Bios Equity II) is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813845 BIOS CAPITAL MANAGEMENT, LP b AF N TX 0 571305 0 571305 571305 N 4.48 PN Shared voting and dispositive power consists of (i) 151,759 Shares directly held by Bios Fund I, (ii) 88,769 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 64,794 Shares directly held by Bios Fund II, (v) 211,566 Shares directly held by Bios Fund II QP and (vi) 28,324 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (Bios Advisors) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001728851 BIOS FUND II NT, LP b WC N DE 0 28324 0 28324 28324 N 0.22 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001716869 BIOS FUND II QP, LP b WC N DE 0 211566 0 211566 211566 N 1.66 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001714576 BIOS FUND II, LP b WC N DE 0 64794 0 64794 64794 N 0.51 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001813311 BP DIRECTORS, LP b OO N DE 0 26093 0 26093 26093 N 0.2 PN Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001700297 BIOS FUND I QP, LP b WC N DE 0 88769 0 88769 88769 N 0.7 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. 0001697316 Bios Fund I, LP b WC N DE 0 151759 0 151759 151759 N 1.19 PN Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I"). Percentage based on 12,758,872 outstanding Shares, consisting of (i) 11,304,697 shares as reported in the Form 10-K filed by the Issuer on April 29, 2026, and (ii) 1,454,175 shares as reported in the Form 8-K filed by the Issuer on May 14, 2026. Common Stock, par value $0.0001 per share Lantern Pharma Inc. 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 This Amendment No. 7 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statements on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), March 1, 2024 ("Amendment No. 3"), June 12, 2025 ("Amendment No. 4"), February 23, 2026 ("Amendment No. 5"), April 16, 2026 ("Amendment 6") and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, and Amendment No. 6, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer"). The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. Except as described in this Amendment No. 7, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D. Not applicable. Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020). BIOS ADVISORS GP, LLC /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 AARON G.L. FLETCHER /s/ John Fucci John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher 05/15/2026 CAVU MANAGEMENT, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 CAVU ADVISORS, LLC /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 LESLIE W. KREIS /s/ John Fucci John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr. 05/15/2026 BIOS EQUITY PARTNERS, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS EQUITY PARTNERS II, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS CAPITAL MANAGEMENT, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS FUND II NT, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS FUND II QP, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS FUND II, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BP DIRECTORS, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS FUND I QP, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 Bios Fund I, LP /s/ John Fucci John Fucci/Attorney-in-Fact 05/15/2026 BIOS FUND II, LP By: Bios Equity Partners II, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS FUND II QP, LP By: Bios Equity Partners II, LP, itsgeneral partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP,LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II NT, LPBy: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its generalpartner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorneyin-Fact BIOS INCYSUS CO-INVEST I, LP By: Bios Equity Partners II, LP, its general partnerBy: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its generalpartner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III, LP By: Bios EquityPartners III, LP, its general partner By: Bios Capital Management, LP, its general partner By:Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOSFUND III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS FUND III NT, LP By: Bios Equity Partners III, LP, itsgeneral partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP,LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS CLINICALOPPORTUNITY FUND, LP By: Bios Equity COF, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner BPDIRECTORS, LP By: Bios Equity Partners, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS II, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in Fact BIOS EQUITY PARTNERS III, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY COF, LP By: Bios Capital Management, LP, itsgeneral partner By: Bios Advisors GP, LLC, its general partner CAVU MANAGEMENT, LP By:Cavu Advisors, LLC, its general partner By: /s/ John Fucci Attorney-in-Fact BIOS CAPITALMANAGEMENT, LP By: Bios Advisors GP, LLC its general partner By: /s/ John Fucci Attorney in-Fact